pharma · Advanced Solid Tumors · Non-Hodgkin's Lymphoma
Liposome Company
Taiwan Liposome Company
Liposome Company clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Employees
- 21
- Programs
- 6
- Drugs
- 7
- Patents
- 0
Liposome Company projects
6 ClinicalTrials.gov programs sponsored by Liposome Company.
Liposome Company has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Cyclophosphamide Doxorubicin Vincristine Lamivudine
Taiwan Liposome Company
Non-Hodgkin's Lymphoma
1 trial -
Lipotecan
Taiwan Liposome Company
HepatoCellular Carcinoma
1 trial -
BEL-X-HG
Taiwan Liposome Company
Advanced Solid Tumors
1 trial -
Ga68-Dolacga Injection
Taiwan Liposome Company
Safety Issues
1 trial -
Lipotecan
Taiwan Liposome Company
Advanced Solid Tumors
1 trial -
Magnesium Citrate
Taiwan Liposome Company
Cognitive Function
1 trial
Frequently asked questions
How many clinical projects does Liposome Company have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.